[go: up one dir, main page]

BRPI0519111A2 - mÉtodos para tratar o mal de parkinson, para melhorar um sintoma do mal de parkinson e para melhorar um sintoma de uma doenÇa ou distérbio cognitivos, e, uso de um ligando seletivo de erbeta - Google Patents

mÉtodos para tratar o mal de parkinson, para melhorar um sintoma do mal de parkinson e para melhorar um sintoma de uma doenÇa ou distérbio cognitivos, e, uso de um ligando seletivo de erbeta

Info

Publication number
BRPI0519111A2
BRPI0519111A2 BRPI0519111-4A BRPI0519111A BRPI0519111A2 BR PI0519111 A2 BRPI0519111 A2 BR PI0519111A2 BR PI0519111 A BRPI0519111 A BR PI0519111A BR PI0519111 A2 BRPI0519111 A2 BR PI0519111A2
Authority
BR
Brazil
Prior art keywords
disease
symptom
improving
parkinson
methods
Prior art date
Application number
BRPI0519111-4A
Other languages
English (en)
Inventor
Mark Day
Heather A Harris
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0519111A2 publication Critical patent/BRPI0519111A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

MÉTODOS PARA TRATAR O MAL DE PARKINSON, PARA MELHORAR UM SINTOMA DO MAL DE PARKJNSON E PARA MELHORAR UM SINTOMA DE UMA DOENÇA OU DISTéRBIO COGNITIVOS, E, USO DE UM LIGANDO SELETIVO DE ERBETA. Esta invenção diz respeito a métodos para tratar doenças cognitivas ou distúrbios e sintomas destas com beta agonistas seletivos de estrogênio.
BRPI0519111-4A 2004-12-17 2005-12-15 mÉtodos para tratar o mal de parkinson, para melhorar um sintoma do mal de parkinson e para melhorar um sintoma de uma doenÇa ou distérbio cognitivos, e, uso de um ligando seletivo de erbeta BRPI0519111A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63714404P 2004-12-17 2004-12-17
PCT/US2005/045375 WO2006065968A2 (en) 2004-12-17 2005-12-15 The uses of estrogen beta agonists to treat cognitive diseases

Publications (1)

Publication Number Publication Date
BRPI0519111A2 true BRPI0519111A2 (pt) 2008-12-23

Family

ID=36143266

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519111-4A BRPI0519111A2 (pt) 2004-12-17 2005-12-15 mÉtodos para tratar o mal de parkinson, para melhorar um sintoma do mal de parkinson e para melhorar um sintoma de uma doenÇa ou distérbio cognitivos, e, uso de um ligando seletivo de erbeta

Country Status (20)

Country Link
US (1) US20060135574A1 (pt)
EP (1) EP1824478A2 (pt)
JP (1) JP2008524236A (pt)
KR (1) KR20070086329A (pt)
CN (1) CN101321524A (pt)
AR (1) AR051844A1 (pt)
AU (1) AU2005316561A1 (pt)
BR (1) BRPI0519111A2 (pt)
CA (1) CA2590258A1 (pt)
GT (1) GT200500370A (pt)
IL (1) IL183604A0 (pt)
MX (1) MX2007007347A (pt)
NI (1) NI200700152A (pt)
NO (1) NO20072658L (pt)
PA (1) PA8656601A1 (pt)
PE (1) PE20061113A1 (pt)
RU (1) RU2007120254A (pt)
TW (1) TW200637545A (pt)
WO (1) WO2006065968A2 (pt)
ZA (1) ZA200705103B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071043A1 (es) * 2006-02-14 2007-10-23 Wyeth Corp FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß
US10149982B2 (en) 2009-03-11 2018-12-11 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
WO2010105035A2 (en) * 2009-03-11 2010-09-16 University Of South Florida Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
US10758496B2 (en) * 2014-09-02 2020-09-01 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
CA3057369A1 (en) * 2017-03-30 2018-10-04 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
IL145839A0 (en) * 1999-04-16 2002-07-25 Astrazeneca Ab ESTROGEN RECEPTOR-β LIGANDS
EP1341768A1 (en) * 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic benzimidazole compounds
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
EP1310799B1 (en) * 2001-11-07 2005-12-21 Schering AG In vitro screening for ligands of the estrogen receptor
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
WO2004026290A1 (en) * 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7157492B2 (en) * 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
EP1761513A1 (en) * 2004-07-01 2007-03-14 Wyeth Tetracyclic compounds as estrogen ligands

Also Published As

Publication number Publication date
NO20072658L (no) 2007-09-12
AU2005316561A1 (en) 2006-06-22
ZA200705103B (en) 2009-11-25
KR20070086329A (ko) 2007-08-27
WO2006065968A8 (en) 2008-09-12
PE20061113A1 (es) 2006-11-06
AR051844A1 (es) 2007-02-14
CN101321524A (zh) 2008-12-10
CA2590258A1 (en) 2006-06-22
JP2008524236A (ja) 2008-07-10
PA8656601A1 (es) 2006-12-07
EP1824478A2 (en) 2007-08-29
GT200500370A (es) 2006-07-13
MX2007007347A (es) 2007-07-13
IL183604A0 (en) 2007-10-31
NI200700152A (es) 2008-06-17
TW200637545A (en) 2006-11-01
WO2006065968A3 (en) 2008-04-10
RU2007120254A (ru) 2009-01-27
WO2006065968A2 (en) 2006-06-22
US20060135574A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
BRPI0511477A (pt) compostos e composições como moduladores de ppar
BRPI0606466A2 (pt) amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
BRPI0812889A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal.
MA32888B1 (fr) Anticorps anti-igf
NO20076344L (no) Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
BRPI0915979A2 (pt) Métodos para melhorar a qualidade de vida de um animal, para aumentar a qualidade de vida de um animal, para tratar um animal sofrendo de um distúrbio ou doença, para medir o aumento na qualidade de vida de um animal, e para identificar um animal que pode se beneficiar da alimentação com uma composição de ração, e, kit.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
EA200600920A1 (ru) Иммуносорбентные исследования крови для оценки пароксизмальных церебральных разрядов
WO2005030678A3 (en) AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
WO2007044695A3 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
ECSP066559A (pt)
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
WO2007134818A3 (en) Method for diagnosing mitochondrial dysfunction
BRPI0519111A2 (pt) mÉtodos para tratar o mal de parkinson, para melhorar um sintoma do mal de parkinson e para melhorar um sintoma de uma doenÇa ou distérbio cognitivos, e, uso de um ligando seletivo de erbeta
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
WO2007030761A3 (en) Acyclic 1,4-diamines and uses thereof
BRPI0414365A (pt) composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes
ATE384727T1 (de) Pyrimdobenzimidazolderivate und verwendung damit als agonisten oder antagonisten von melanocortinrezeptoren
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.